ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals (OTCBB:RXHN.OB), a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, disorders of the central nervous system and unmet medical needs, today announced the conclusion of the Phase I clinical trials of its leading oncology candidate, RX-0201.
